Home › Funds › DAFNA Capital Management LLC › AQST

DAFNA Capital Management LLC position in AQST

AQUESTIVE THERAPEUTICS INC · Health Care

DAFNA Capital Management LLC reported holding 640,915 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 0.63% of its reported portfolio and ranking #37 among its reported holdings. DAFNA Capital Management LLC has disclosed AQST holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)640.91K sh
Reported value held$2.97M
Portfolio Weight0.63%
First reportedQ1 2024
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How DAFNA Capital Management LLC's AQST position evolved

DAFNA Capital Management LLC first disclosed a stake in AQST in Q1 2024 at 500,000 shares (US$2.1M). The position peaked in Q3 2026 at 640,915 shares, worth US$3.0M. Across 11 filings, DAFNA Capital Management LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 640,915 shares valued at US$3.0M — a reduction of -5,000 shares quarter over quarter.. Notable position changes include a 78% trim in Q4 2024 (shares fell 19% over the following quarter), a 261% increase in Q3 2025 (shares rose 16% over the following quarter), a 75% increase in Q2 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 500.00K $2.13M New
Q2 2024 530.00K $1.38M Add
Q3 2024 589.56K $2.94M Add
Q4 2024 127.00K $452.12K Reduce
Q1 2025 142.00K $411.80K Add
Q2 2025 142.00K $470.02K Hold
Q3 2025 512.59K $2.87M Add
Q4 2025 375.92K $2.43M Reduce
Q1 2026 368.42K $1.53M Reduce
Q2 2026 645.91K $2.69M Add
Q3 2026 640.91K $2.97M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AQST and 13F data

AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Samsara BioCapital, LLC (US$11.3M), Rosalind Advisors, Inc. (US$9.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AQST

All AQST fund holders →

FAQ

How long has DAFNA Capital Management LLC held AQST?

DAFNA Capital Management LLC has disclosed AQST holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is DAFNA Capital Management LLC's current position in AQST?

As of Q3 2026, DAFNA Capital Management LLC holds 640.91K shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $2.97M, representing 0.63% of its reported portfolio and ranking #37.

Has DAFNA Capital Management LLC been buying or selling AQST?

In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC reduced its position in AQST. The position peaked in Q3 2026 at 640.91K shares.

Which other funds hold AQST?

Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Rosalind Advisors, Inc., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.